XXII

22nd Century Group, Inc. (XXII) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2025. 22nd Century Group, Inc. is a tobacco products company focused on reduced nicotine content (RNC) products, holding the first FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette. The company operates as a single reportable segment, providing contract manufacturing services (CMO) and selling proprietary VLN® and SPECTRUM® brands. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Q3 2025 Net Income includes a $9.252M gain from discontinued operations (Dorchester settlement). Net loss from continuing operations was $3.763M.

Material Changes vs. Prior Period

• Revenue Decline: Net revenue decreased 32.5% in Q3 and 31.0% in the nine months ended Sept 30, 2025, compared to the prior year. This was driven by a shift in product mix, lower volumes in filtered cigars, and pricing adjustments in contract manufacturing agreements.
• Discontinued Operations Gain: The company recorded a significant $9.252M pre-tax gain in Q3 2025 from discontinued operations, primarily due to the settlement of the Dorchester insurance litigation regarding the 2022 facility fire. This turned a continuing operations loss into a net income for the quarter.
• Debt Elimination: The company fully repaid and terminated its Senior Secured Credit Facility in September 2025 using proceeds from a Series A preferred stock offering. Long-term debt is now $0.
• Expense Reduction: Operating expenses decreased 22.8% in Q3 and 25.8% in the nine-month period, driven by reductions in SG&A (legal, consulting) and R&D costs.
• Capital Structure: Issued Series A Convertible Preferred Stock (classified as mezzanine equity) and warrants, resulting in significant dilution potential. Outstanding warrants increased to over 11.4 million shares.

Guidance, Outlook, and Risks

• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year following the report date due to significant accumulated deficits ($396.1M) and negative cash flows from operations ($10.5M for 9M 2025).
• Liquidity Strategy: The company is pursuing financing strategies including equity/debt issuance and asset sales. Recent cash inflows included $9.893M from the Series A offering and $9.5M from the insurance settlement (received Oct 2025).
• Product Launch: Full-scale launch of VLN® cigarettes in over 1,700 convenience stores is expected to begin in Q4 2025.
• Risks: Key risks include the inability to raise additional capital, market acceptance of reduced nicotine products, regulatory changes, and the high dilution risk from outstanding warrants with anti-dilution provisions.

Investor Verification Checklist

• Going Concern Status: Verify the company's ability to secure funding beyond current cash reserves ($4.8M) given the substantial doubt disclosure.
• Discontinued Operations Impact: Confirm that the Q3 net income is non-recurring and driven by the one-time insurance settlement, not core operations.
• Dilution Risk: Review the terms of the 11.4M+ outstanding warrants, specifically the "Zero Exercise Price Exercise" provisions and anti-dilution ratchets.
• Debt Repayment Source: Confirm the sustainability of operations after using Series A proceeds to extinguish the Senior Secured Credit Facility.
• Revenue Mix: Monitor the transition from contract manufacturing to proprietary VLN® brand sales to assess margin improvement potential.